Page 1921 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

1348 Index

Mumps virus, 674 Neck surgery emergencies, 1076 Neuromuscular junction blockade, prolonged,
Monro-Kellie doctrine, 788 Necrosis, 328 768–769
Murray Valley encephalitis virus, 672 cellular, 1124 Neuroprotection, spinal injuries and, 1150
Muscle relaxants and airway management in Necrotizing enterocolitis, 616–617, 868 Neuropsychological morbidities, health-
intensive-care unit, 388 Necrotizing fasciitis, 690, 691–694, 692f, 693f, related quality of life and,
Myasthenia gravis (MG), 821, 825–826, 1265 1296–1297, 1297f 105–106
Mycobacterium avium complex, 640–641 etiology of, 692 Neurosurgical management issues, spinal
Mycobacterium tuberculosis, 635–636, 675 management of, 693–694 injuries and, 1146–1147, 1146f,
during pregnancy, 1265 pathogenesis of, 691–692 1147f, 1148f, 1149–1150, 1149f
Mycophenolate mofetil, 1089 presentation of, 692–693 Neutropenia, 601–603, 602f, 893–894
use of, in critically ill patient, 1251 sepsis and, 567 in burn patients, 1187
https://kat.cr/user/tahir99/
Mycoplasma pneumoniae, 675, 676 Needle cricothyroidotomy, 392 Neutropenic fevers, 606–615
Mycotic aneurysms, 597, 686–687 Negative pressure ventilation, 380 diagnosis of, 606–608, 607t, 608f
Myelitis, 665 Neisseria meningitides, meningitis empirical antimicrobial therapy for,
Myeloid cells, soluble triggering receptor due to, 652 609–615, 610t, 611t, 614t
expressed on, 567 Neonatal encephalitis, 670 infections and bacterial pathogens causing,
Myeloid sarcoma, 867 Neonatal thyrotoxicosis, thyroid disease and, 605–606
Myeloma, multiple, 947 995–996 risk assessment in, 608–609
Myelosuppression, 601–603, 602f, Neostigmine, 1007–1008 Neutropenic host, infection prevention in,
893–894, 894t Nephritis, acute focal bacterial, 700 622–624
Myocardial acidosis, 272 Nephrogenic systemic sclerosis, risk of, 209 Neutropenics, 603
Myocardial function, maximizing, 315–316 Nephrostomy, percutaneous, 211–212, Neutrophilic eccrine hidradenitis, 1285
Myocardial hypoxia, 272 211f, 212f New directions, sepsis and, 575–576
Myocardial infarction, 294 Nephrotoxic injury, 920 Nicardipine, 364
induced hypothermia in, 177 Neurally adjusted ventilatory assistance, 438 Nikolsky sign, 1291, 1294, 1298
Myocardial ischemia, 272, 293–308, 1069 Neuraxial opiate analgesia, 147–148 Nipah virus, 674
cardiac biomarkers, 295–296 Neurocognitive impairments, 111–113 Nitrates, 297, 301
echocardiography, 296 Neurogenesis, 1124 Nitric oxide, 316–317
electrocardiogram, 295 Neurogenic hypotension, 1144 Nitric oxide inhibitor, 1279
hemodynamic monitoring, 296–297, 296t Neurogenic shock, 260 No Code order, 128
management of angina, 297–298 Neuroleptic malignant syndrome, 560–561 Nondepolarizing neuromuscular blocking
non-ST elevation myocardial infarction, Neurologic, electrical trauma and, 1178 agents (NMBs), 154
302–305 Neurological outcome, spinal injuries Nondialytic supportive care of acute renal
pathophysiology, 294, 294f and, 1152 failure, 931–932, 932t
signs and symptoms, 294–295 Neurologic complications, 899–900 Nonhemorrhagic hypovolemia, 237
silent, 295 Neurologic criteria, declaration of death Noninflammatory diarrhea, 706
ST-elevation myocardial infarction, 298– using, 838 Noninvasive leg studies in diagnosing
302 Neurologic emergencies, 875–877, 875t, 876t pulmonary embolic
terminology, 293–294 Neurologic examinations, 831–832 disorders, 325
Myoclonic jerks, 781 Neurologic injury Noninvasive positive pressure ventilation
Myoclonus in postanoxic coma, 781 after carotid revascularization, (NPPV), 501
Myoglobin, 1178 1075–1076, 1075t in critically ill traveler, 715–716
Myonecrosis, 690, 694–695, 694f extremity trauma and, 1173–1174 Noninvasive ventilation, 160, 377–384
etiology, 694 Neurologic manifestations in HIV-infected acute exacerbation of chronic respiratory
management of, 695 patients, 637–638, 637–638t failure in, 379–381
pathogenesis of, 694 Neurologic states resembling brain cardiogenic pulmonary edema in, 381
presentation of, 694–695 death, 839 epidemiology of, 378–379, 378f
Myopathy, 768, 768t Neuromonitoring issues, head injury equipment in, 379
Myotonia, 1062 and, 1129 fiberoptic bronchoscopy in, 383–384
Myxedema coma Neuromuscular blockade, 1061 hypoxemic respiratory failure in, 381–382
diagnosis of, 988, 989t complications of, 155 new modes of, 383
pulmonary and cardiovascular monitoring level of, 154–155 patients who should not be intubated, 383
complications, 988–989 Neuromuscular blocking agents, 154–155 patients with severe acute asthma, 383
thyroid disease and, 988–990, 989t nondepolarizing, 154 postextubation respiratory failure in, 383
treatment of, 989–990 for tetanus, 732 postoperative respiratory failure in, 383
Neuromuscular diseases leading to respiratory preoxygenation before intubation, 382
N failure, 821–828 rationale and objective in, 377–378
Naloxone, 1196 general assessment and management, subgroups in, 382
Narrative, use of, by medical 821–828, 821t, 822t trauma in, 384
anthropologists, 116 of acute respiratory failure secondary to, weaning in, 383
Nasopharynx, 404 823–828 Nonobstructive jaundice, 999
Nasotracheal intubation, 389 respiratory muscle weakness, Nonocclusive mesenteric ischemia, 1039
National Quality Forum, 11 821–823, 823f Nonphysician providers, intensive-care unit
Native valve endocarditis (NVE), 594 Neuromuscular dysfunction, 106, 106f staffing of, as physician extenders,
Near-infrared spectroscopy (NIRS), 244 Neuromuscular injury, adjunctive testing for, 17–19, 17t, 18t
Neck, life-threatening infections of, 676–688 766–769, 767f, 768t Nonpolio enteroviruses, 673

Index.indd 1348 23-01-2015 15:33:53